Physician profile
Rose M Sinclair
NPI 1184233447
$1,152.69
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.77 · 2023: $449 · 2024: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $94.65 | 2023-2024 | |
| Insulet Corporation | $84.51 | 2023-2024 | Omnipod |
| Glaxosmithkline, LLC. | $83.30 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $80.86 | 2023-2024 | Farxiga |
| Exact Sciences Corporation | $76.91 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $74.30 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $74.08 | 2023-2024 | Gardasil 9, Proquad, Vaxelis |
| Dexcom, INC. | $69.80 | 2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $63.76 | 2023-2024 | Wegovy |
| Lilly USA, LLC | $57.72 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $48.70 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.91 | 2023-2024 | Jardiance, Tradjenta |
| Abbvie INC. | $43.00 | 2023 | |
| Inspire Medical Systems, INC. | $40.76 | 2024 | Inspire |
| Amgen INC. | $35.35 | 2023-2024 | Otezla, Repatha, Prolia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.53 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.77 | 2022 | |
| Sumitomo Pharma America, INC. | $22.01 | 2024 | Gemtesa |
| Biomarin Pharmaceutical INC. | $21.28 | 2024 | Voxzogo 1.2mg |
| Daiichi Sankyo INC. | $20.72 | 2024 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.52 | 2024 | Caplyta |
| Sanofi-Aventis U.S. LLC | $17.83 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.42 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Sinclair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.